Cargando…
Rational combinations of immunotherapeutics that target discrete pathways
An effective anti-tumor immune response requires the coordinated action of the innate and adaptive phases of the immune system. Critical processes include the activation of dendritic cells to present antigens, produce cytokines including type I interferons, and express multiple costimulatory ligands...
Autores principales: | Spranger, Stefani, Gajewski, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019905/ https://www.ncbi.nlm.nih.gov/pubmed/24829752 http://dx.doi.org/10.1186/2051-1426-1-16 |
Ejemplares similares
-
Tumor-intrinsic oncogene pathways mediating immune avoidance
por: Spranger, Stefani, et al.
Publicado: (2015) -
Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013) -
A new paradigm for tumor immune escape: β-catenin-driven immune exclusion
por: Spranger, Stefani, et al.
Publicado: (2015) -
Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors
por: Horton, Brendan, et al.
Publicado: (2014) -
Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer
por: Sweis, Randy F, et al.
Publicado: (2015)